Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Verastem Inc (VSTM)

Verastem Inc (VSTM)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 80,298
  • Shares Outstanding, K 74,350
  • Annual Sales, $ 26,720 K
  • Annual Income, $ -72,430 K
  • 60-Month Beta 2.90
  • Price/Sales 3.03
  • Price/Cash Flow N/A
  • Price/Book 3.77

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate -0.33
  • Number of Estimates 1
  • High Estimate -0.33
  • Low Estimate -0.33
  • Prior Year -0.37
  • Growth Rate Est. (year over year) +10.81%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.02 +1.96%
on 11/12/19
1.38 -24.64%
on 10/24/19
-0.05 (-4.59%)
since 10/11/19
3-Month
1.02 +1.96%
on 11/12/19
1.45 -28.28%
on 08/27/19
-0.27 (-20.61%)
since 08/12/19
52-Week
1.02 +1.96%
on 11/12/19
5.71 -81.79%
on 11/19/18
-4.04 (-79.53%)
since 11/12/18

Most Recent Stories

More News
Verastem Oncology Announces Private Exchange of Approximately $114.3 Million of its 5.00% Convertible Senior Notes due 2048 for 5.00% Convertible Senior Second Lien Notes Due 2048

Verastem, Inc. (NASDAQ: VSTM) (the "Company") today announced that it has entered into privately negotiated agreements among the Company and a limited number of investors who are accredited investors (within...

VSTM : 1.03 (-4.63%)
Verastem Oncology to Present Phase 2 PRIMO Study Data Evaluating Duvelisib in Relapsed or Refractory Peripheral T-Cell Lymphoma at the American Society of Hematology 2019 Annual Meeting

--PRIMO Expansion Phase To Investigate Duvelisib 75mg Twice Daily for Two Cycles, Followed by 25mg Twice Daily

VSTM : 1.03 (-4.63%)
Vericel Announces Appointment of Sean C. Flynn as Vice President and General Counsel

Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced the appointment of Sean C. Flynn as Vice President and General Counsel....

ABMD : 223.54 (+1.57%)
VSTM : 1.03 (-4.63%)
VCEL : 19.20 (+0.26%)
Verastem (VSTM) Reports Q3 Loss, Misses Revenue Estimates

Verastem (VSTM) delivered earnings and revenue surprises of 16.67% and -1.83%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

VSTM : 1.03 (-4.63%)
Verastem Oncology Reports Third Quarter 2019 Financial Results and Recent Company Progress

--Cash, Cash Equivalents and Short-Term Investments of $160.2 Million as of September 30, 2019

VSTM : 1.03 (-4.63%)
Verastem Oncology Announces COPIKTRA(TM) (Duvelisib) Presentations at the Lymphoma & Myeloma 2019 International Congress

Verastem, Inc. (Nasdaq:VSTM) (Verastem Oncology or the Company), a biopharmaceutical company focused on developing and commercializing medicines seeking to improve the survival and quality of life of cancer...

VSTM : 1.03 (-4.63%)
Verastem Oncology to Announce Third Quarter 2019 Financial Results and Corporate Update on October 29, 2019

Verastem, Inc. (Nasdaq:VSTM) (Verastem Oncology or the Company), a biopharmaceutical company focused on developing and commercializing medicines seeking to improve the survival and quality of life of cancer...

VSTM : 1.03 (-4.63%)
Biotech Stock Roundup: GILD's Descovy Label Expansion Gets FDA Nod & Other Updates

Key highlights of the past week include label expansion of drugs, licensing deals and more.

PFE : 36.97 (+0.11%)
VSTM : 1.03 (-4.63%)
ACAD : 46.33 (+2.41%)
GILD : 64.32 (-0.50%)
IONS : 56.98 (+0.58%)
AKCA : 19.23 (-0.72%)
Verastem's (VSTM) Copiktra Gets Orphan Drug Designation

Verastem's (VSTM) Copiktra gets orphan drug designation from the FDA for use in the treatment of T-Cell lymphoma.

SNY : 46.05 (+0.41%)
MRK : 84.12 (+1.01%)
VSTM : 1.03 (-4.63%)
INFI : 0.91 (-2.15%)
Verastem Oncology Announces Dosing of First Patient in Yakult Honsha Co., Ltd.'s Japanese Bridging Study Evaluating COPIKTRA(R) (Duvelisib) in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Verastem, Inc. (Nasdaq: VSTM), (Verastem Oncology or the Company), a biopharmaceutical company focused on developing and commercializing medicines seeking to improve the survival and quality of life of...

VSTM : 1.03 (-4.63%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Soft. Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Trade VSTM with:

Business Summary

Verastem, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing drugs to improve outcomes for patients with cancer. Its programs target the focal adhesion kinase (FAK) and the phosphoinositide 3-kinase (PI3K)/mTOR signaling pathways. Its lead FAK inhibitor is defactinib...

See More

Key Turning Points

2nd Resistance Point 1.11
1st Resistance Point 1.10
Last Price 1.03
1st Support Level 1.07
2nd Support Level 1.05

See More

52-Week High 5.71
Fibonacci 61.8% 3.92
Fibonacci 50% 3.37
Fibonacci 38.2% 2.81
Last Price 1.03
52-Week Low 1.02

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar